Literature DB >> 25096169

Off-label drug use as a consent and health regulation issue in New Zealand.

Rebecca Julia Cook1.   

Abstract

The term "off-label drug use" refers to drugs that have not yet acquired "approved" status or drugs that have acquired "approved" status but are used with a different dosage, route, or administration method other than that for which the drug has been approved. In New Zealand, the Medicines Act 1981 specifically allows for off-label drug use. However, this authority is limited by the Health and Disability Commissioner (Code of Health and Disability Services Consumers' Rights) Regulations 1996 and the common law, which require that off-label drug use is of an acceptable standard, that the patient should be fully informed, and that the patient should give informed consent. Off-label drug use is an important issue because the current law provides medical practitioners very wide discretionary power, without providing clarification for what is required of the practitioner in exercising his or her discretion in prescribing off-label. This paper discusses possible solutions to this issue, for example, establishing protocol for off-label use, an electronic database of off-label use, and the amendment of legal provisions.

Entities:  

Mesh:

Year:  2014        PMID: 25096169     DOI: 10.1007/s11673-014-9568-6

Source DB:  PubMed          Journal:  J Bioeth Inq        ISSN: 1176-7529            Impact factor:   1.352


  3 in total

1.  Prohibition against off-label drug promotion challenged.

Authors:  Cal Woodward
Journal:  CMAJ       Date:  2012-02-21       Impact factor: 8.262

2.  Off-label use of quetiapine in New Zealand--a cause for concern?

Authors:  Paul Glue; Chris Gale
Journal:  N Z Med J       Date:  2011-06-10

3.  Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children.

Authors:  S Conroy; I Choonara; P Impicciatore; A Mohn; H Arnell; A Rane; C Knoeppel; H Seyberth; C Pandolfini; M P Raffaelli; F Rocchi; M Bonati; G Jong; M de Hoog; J van den Anker
Journal:  BMJ       Date:  2000-01-08
  3 in total
  1 in total

1.  "Can a Company be Bitchy?" Corporate (and Political and Scientific) Social Responsibility.

Authors:  Leigh E Rich; Michael A Ashby
Journal:  J Bioeth Inq       Date:  2015-05-28       Impact factor: 1.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.